hVIVO achieves primary endpoint in phase II vaccine flu study

This article was originally published here

FLU-v is being developed by Imutex, hVIVO’s 49% joint venture with the SEEK Group. Following additional analysis of the samples from the study by the National Institute of

The post hVIVO achieves primary endpoint in phase II vaccine flu study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply